Aliases & Classifications for Ocular Hypertension

MalaCards integrated aliases for Ocular Hypertension:

Name: Ocular Hypertension 12 51 41 14 69

Classifications:



External Ids:

Disease Ontology 12 DOID:9282
ICD10 32 H40.05
ICD9CM 34 365.04
MeSH 41 D009798
NCIt 46 C3285
UMLS 69 C0028840

Summaries for Ocular Hypertension

Disease Ontology : 12 An eye disease that is characterized by elevated intraocular pressure in the absence of optic nerve damage or visual field loss.

MalaCards based summary : Ocular Hypertension is related to open-angle glaucoma and glaucoma, primary open angle, and has symptoms including eye manifestations An important gene associated with Ocular Hypertension is MYOC (Myocilin), and among its related pathways/superpathways are Fluid shear stress and atherosclerosis and TGF-beta Signaling Pathways. The drugs Dexamethasone and Topiramate have been mentioned in the context of this disorder. Affiliated tissues include eye, testes and retina, and related phenotypes are homeostasis/metabolism and mortality/aging

Wikipedia : 72 Ocular hypertension is the presence of elevated fluid pressure inside the eye (intraocular pressure),... more...

Related Diseases for Ocular Hypertension

Diseases related to Ocular Hypertension via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 62)
# Related Disease Score Top Affiliating Genes
1 open-angle glaucoma 30.6 MYOC OPTN PTGFR TMCO1
2 glaucoma, primary open angle 30.4 MYOC OPTN PTGFR TMCO1
3 glaucoma 3, primary congenital, a 10.8
4 glaucoma 3, primary infantile, b 10.8
5 retinitis 10.4
6 glaucoma 1, open angle, a 10.1 MYOC OPTN
7 excessive tearing 10.1 MYOC OPTN
8 intraocular pressure quantitative trait locus 10.1 MYOC OPTN
9 apparent mineralocorticoid excess 10.0 HSD11B1 HSD11B2 NR3C1
10 cataract 10.0
11 uveitis 10.0
12 endotheliitis 10.0
13 periosteal osteogenic sarcoma 10.0 FOS JUN
14 glycogen storage disease vi 9.9 FOS G6PC
15 ocular hypotension 9.9
16 exfoliation syndrome 9.9
17 photokeratitis 9.8 FOS JUN
18 glaucoma, normal tension 9.8
19 hydrops, lactic acidosis, and sideroblastic anemia 9.8
20 low tension glaucoma 9.8
21 neuropathy 9.8
22 retinal vein occlusion 9.8
23 neuroretinitis 9.8
24 macular retinal edema 9.8
25 complement hyperactivation, angiopathic thrombosis, and protein-losing enteropathy 9.7
26 aging 9.7
27 mungan syndrome 9.7
28 arthritis 9.7
29 retinal ischemia 9.7
30 thrombosis 9.7
31 choroiditis 9.7
32 scleritis 9.7
33 ischemia 9.7
34 cavernous sinus thrombosis 9.7
35 thyroiditis 9.7
36 retinal degeneration 9.7
37 osteoporosis 9.6 CA2 FOS HSD11B1 JUN NR3C1
38 blood group--diego system 9.5
39 blood group, i system 9.5
40 coloboma of macula 9.5
41 keratitis, hereditary 9.5
42 retinal detachment 9.5
43 glaucoma-related pigment dispersion syndrome 9.5
44 anxiety 9.5
45 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 9.5
46 graft-versus-host disease 9.5
47 diabetes mellitus 9.5
48 ischemic optic neuropathy 9.5
49 keratoconus 9.5
50 leukemia 9.5

Comorbidity relations with Ocular Hypertension via Phenotypic Disease Network (PDN):


Glaucoma, Primary Open Angle

Graphical network of the top 20 diseases related to Ocular Hypertension:



Diseases related to Ocular Hypertension

Symptoms & Phenotypes for Ocular Hypertension

UMLS symptoms related to Ocular Hypertension:


eye manifestations

MGI Mouse Phenotypes related to Ocular Hypertension:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.21 CA2 EPO FKBP5 FOS G6PC HSD11B1
2 mortality/aging MP:0010768 10.1 HSD11B2 JUN NR3C1 OPTN SRSF3 TMCO1
3 immune system MP:0005387 10.06 CA2 EPO FOS HSD11B1 JUN NR3C1
4 nervous system MP:0003631 9.91 RLBP1 TMCO1 TXN2 JUN NR3C1 CA2
5 liver/biliary system MP:0005370 9.85 EPO G6PC HSD11B1 JUN NR3C1 SRSF3
6 normal MP:0002873 9.81 EPO FKBP5 FOS G6PC HSD11B2 JUN
7 renal/urinary system MP:0005367 9.43 CA2 FKBP5 G6PC HSD11B2 NR3C1 SRSF3
8 skeleton MP:0005390 9.23 CA2 EPO FOS G6PC JUN NR3C1

Drugs & Therapeutics for Ocular Hypertension

Drugs for Ocular Hypertension (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 273)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3 50-02-2 5743
2
Topiramate Approved Phase 4 97240-79-4 5284627
3
Timolol Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 26839-75-8 5478 33624
4
Ephedrine Approved Phase 4,Phase 3,Phase 1,Phase 2 299-42-3 9294
5
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
6
Acetazolamide Approved, Vet_approved Phase 4,Phase 3,Phase 2 59-66-5 1986
7
Pilocarpine Approved, Investigational Phase 4,Phase 3 92-13-7, 54-71-7 5910
8
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
9
Brinzolamide Approved Phase 4,Phase 3,Phase 2 138890-62-7 68844
10
Dorzolamide Approved Phase 4,Phase 3,Phase 2,Phase 1 120279-96-1 5284549 3154
11
Triamcinolone Approved, Vet_approved Phase 4,Phase 2,Phase 3 124-94-7 31307
12
Latanoprost Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 130209-82-4 5311221 5282380
13
Pseudoephedrine Approved Phase 4,Phase 3,Phase 1,Phase 2 90-82-4 7028
14
Apraclonidine Approved Phase 4,Phase 3 66711-21-5 2216
15
Bimatoprost Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 155206-00-1 5311027
16
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
17
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2 216974-75-3
18
Travoprost Approved Phase 4,Phase 3,Phase 2,Phase 1 157283-68-6 5282226
19
Clonidine Approved Phase 4 4205-90-7 2803
20
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
21
Tobramycin Approved, Investigational Phase 4 32986-56-4 36294 5496
22
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2 1994-09-7, 94-09-7 2337
23
Loteprednol Approved Phase 4 129260-79-3, 82034-46-6 9865442 444025
24
Carteolol Approved Phase 4,Phase 3,Phase 1 51781-06-7 2583
25
Ranibizumab Approved Phase 4,Phase 3,Phase 2,Phase 1 347396-82-1 459903
26
Dipivefrin Approved Phase 4,Phase 3 52365-63-6 3105
27
Sorbitol Approved Phase 4 50-70-4 5780
28
Nitrous oxide Approved, Vet_approved Phase 4,Early Phase 1 10024-97-2 948
29
Atropine Approved, Vet_approved Phase 4 5908-99-6, 51-55-8 174174
30
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
31
Choline Approved, Nutraceutical Phase 4 62-49-7 305
32
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4,Phase 2 68-26-8, 11103-57-4 445354
33 tannic acid Approved, Nutraceutical Phase 4,Phase 3,Phase 2
34
Maleic acid Experimental Phase 4,Phase 3,Phase 1,Phase 2 110-16-7 444266
35 triamcinolone acetonide Phase 4,Phase 2,Phase 3
36 Prednisolone acetate Phase 4
37 Brimonidine Tartrate Phase 4,Phase 3,Phase 2,Phase 1 70359-46-5
38 Dexamethasone acetate Phase 4,Phase 2,Phase 3 1177-87-3
39 Analgesics Phase 4,Phase 1,Phase 2,Early Phase 1
40 Alkylating Agents Phase 4,Phase 2,Phase 3,Phase 1
41 diuretics Phase 4,Phase 3,Phase 2,Phase 1
42 glucocorticoids Phase 4,Phase 2,Phase 3
43 Respiratory System Agents Phase 4,Phase 3,Phase 1,Phase 2
44 Methylprednisolone acetate Phase 4
45 Methylprednisolone Hemisuccinate Phase 4
46 Adrenergic Agents Phase 4,Phase 3,Phase 2,Phase 1
47 Mitogens Phase 4,Phase 2,Phase 3,Phase 1
48 Adrenergic Agonists Phase 4,Phase 3,Phase 2,Phase 1
49 Mitomycins Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
50 Adrenergic alpha-2 Receptor Agonists Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 1158)

# Name Status NCT ID Phase Drugs
1 Generic Travoprost Versus Brand Name Travoprost in Patients With Primary Open Angle Glaucoma or Ocular Hypertension Unknown status NCT02796560 Phase 4 Brand name travoprost;Generic travoprost
2 IntraVitreal Triamcinolone Acetonide: Preventing Raised Eye-pressure by Tracking Elevations After Topical Steroids Unknown status NCT00744666 Phase 4 Prednisolone 1% topical eye drops
3 Efficacy of Selective Laser Trabeculoplasty in Patients Under Treatment With Topical Prostaglandines Unknown status NCT01467440 Phase 4
4 A Study of the iStent in Combo With Cataract Surgery in Newly Diagnosed Open Angle Glaucoma or OH Patients. Unknown status NCT00326066 Phase 4
5 Safety and Efficacy Assessment of Monoprost® in Comparison With Lumigan® 0.01 % and Lumigan® 0.03% Unit Dose Unknown status NCT02017327 Phase 4 Monoprost;Lumigan 0.01%;Lumigan 0.03% Unit Dose
6 Combigan Ophthalmic Solution(Brimonidine 0.2% and Timolol 0.5%)With Latanoprost Compared With Latanoprost Monotherapy Unknown status NCT00442312 Phase 4 Combigan Ophthalmic Solutiom
7 Prospective, Randomized, Controlled Study to Assess Efficacy,Safety, and Tolerability of SLT vs. PLT in Patients With POAG Unknown status NCT02231515 Phase 4
8 Efficiency of XAL-EASE Device in Glaucoma and/or Ocular Hypertension (OHT) Patients, Treated With Xalatan or Xalacom Unknown status NCT01125306 Phase 4
9 One, Two, or Three iStents for the Reduction of Intraocular Pressure in Open-angle Glaucoma Subjects Unknown status NCT01517477 Phase 4
10 Purpose of This Study is to Evaluate the Safety and Efficacy of One, Two, or Three iStents for the Reduction of Intraocular Pressure in Open-angle Glaucoma Subjects Unknown status NCT01252849 Phase 4
11 The Impact of Topical Prostaglandins on the Biomechanical Properties of the Cornea in Patients With Open Angle Glaucoma Unknown status NCT02388360 Phase 4 topical prostaglandin analogs
12 Impact of Timolol/Dorzolamide Therapy on Autoregulation in Glaucoma Patients Unknown status NCT02053298 Phase 4 Timolol & Dorzolamide
13 Micropulse Laser Trabeculoplasty Versus Selective Laser Trabeculoplasty for Treatment of Open Angle Glaucoma Unknown status NCT01956942 Phase 4
14 Comparison of Silicone and Porous Plate Ahmed Glaucoma Valves Unknown status NCT01883856 Phase 4
15 The Laser in Pseudoexfoliation (LIP) Study Unknown status NCT01704989 Phase 4 Prostagladin
16 The Effect of "Eye Drop Guide" on the Success Rate of Eye Drops Self-instillation in Glaucoma Patients Unknown status NCT01704248 Phase 4
17 Efficacy and Safety of Three Different Latanoprost 0,005% Eyedrops in Subjects Affected by Primary Open Angle Glaucoma Unknown status NCT01580254 Phase 4 IOPIZE© Latanoprost eyedrops;GALAXIA© Latanoprost eyedrops;Latanoprost RATIOPHARM© latanoprost eyedrops
18 Open-angle Glaucoma Subjects on One Ocular Hypotensive Medication Randomized to Treatment With Two Trabecular Micro-bypass Stents or Selective Laser Trabeculoplasty Unknown status NCT01444105 Phase 4
19 Evaluation of Safety and Efficacy of Glaucoma Shunt (Aurolab Artificial Drainage Implant) in Refractory Glaucoma Unknown status NCT01401088 Phase 4
20 Choroidal Thickness in Glaucoma Patients and Healthy Controls Unknown status NCT01293474 Phase 4
21 Use of Bevacizumab to Modulate the Outcomes of Trabeculectomy Surgery Unknown status NCT01229202 Phase 4 Bevacizumab
22 Effects of Cosopt on IOP and on Ocular Diastolic Perfusion Pressure Unknown status NCT00796198 Phase 4 Xalatan+Cosopt;Xalatan
23 ALPI vs Medical Therapy Effects on Optic Nerve Structure & Function Unknown status NCT00485238 Phase 4 Intravenous acetazolamide
24 Subconjunctival Bevacizumab to Prevent Bleb Failure After Glaucoma Filtration Surgery Unknown status NCT00468429 Phase 4 Subconjunctival Bevacizumab
25 Ologen (OculusGen)-Glaucoma MMC Control Trial in India Unknown status NCT00449098 Phase 4 Trabeculectomy with MMC
26 The Effect of Education on Patient Compliance Unknown status NCT00376974 Phase 4
27 A Study of the Glaukos Trabecular Micro-bypass Stent in Open Angle Glaucoma Subjects 1 Stent Versus 2 Unknown status NCT00326079 Phase 4
28 Open-angle Glaucoma Subjects on One Topical Hypotensive Medication Randomized to Treatment With One or Two Trabecular Micro-bypass Stents in Conjunction With Cataract Surgery Unknown status NCT01455467 Phase 4
29 Efficacy and Safety Study of Combigan and 0.5% Timoptic in Normal Tension Glaucoma Unknown status NCT01446497 Phase 4 Brimonidine/Timolol mixed combination;Timolol
30 Combined Phacotube vs Phacotrabeculectomy:A Randomized Controlled Trial Unknown status NCT00273221 Phase 4
31 PASCAL Trabeculoplasty Unknown status NCT00804323 Phase 4
32 Relationship Between Topiramate Use and Ocular Angle Status Unknown status NCT00153699 Phase 4 Topiramate
33 Comparison of the Ahmed Glaucoma Valve FP7 and FP8 in Pediatric Glaucoma Unknown status NCT01494974 Phase 4
34 An Open, Non-randomized Pilot Study on the Effect of Preservative Free Tafluprost (Saflutan® Augentropfen) in Patients With Ocular Hypertension or Primary Open Angle Glaucoma With an Uncontrolled Intraocular Pressure of 30 mmHg and More Completed NCT01979913 Phase 4 Saflutan® 15 microgram/ml Augentropfen im Einzeldosisbehältnis
35 Study of the Intraocular Pressure (IOP)-Lowering Efficacy of Azopt 1.0% Compared to Timolol 0.5% in Patients With Glaucoma or Ocular Hypertension Completed NCT00300079 Phase 4 brinzolamide 1.0%
36 24-hour Control of Intraocular Pressure (IOP) in Ocular Hypertension Completed NCT01655758 Phase 4 0.5% timolol;timolol-dorzolamide fixed combination;Latanoprost;Travoprost;Bimatoprost
37 Intraocular Pressure and Tolerability Study of Preservative-free Prostaglandins (Bimatoprost and Latanoprost) on Glaucoma and Ocular Hypertension: European, Multicentric, Investigator-led, Single Masked Study Completed NCT01975714 Phase 4 Preservative-free latanoprost;Preservative-free bimatoprost
38 Mechanism of Action of TRAVATAN 0.004% in Subjects With Glaucoma or Ocular Hypertension Completed NCT00061503 Phase 4 Travoprost
39 Long-Term Safety of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension Completed NCT01298700 Phase 4 bimatoprost 0.01% ophthalmic solution;bimatoprost 0.03% ophthalmic solution
40 Assessment of Intraocular Pressure (IOP) Control in Subjects With Open-Angle Glaucoma or Ocular Hypertension Treated With Travoprost 0.004% (TRAVATAN® Z) or Bimatoprost 0.01% (LUMIGAN®) Completed NCT01464424 Phase 4 Travoprost 0.004% ophthalmic solution;Bimatoprost 0.01% ophthalmic solution
41 A Study of Patients With Primary Open Angle Glaucoma or Ocular Hypertension Switched to Lumigan® UD Monotherapy for Medical Reasons Completed NCT01853085 Phase 4 Bimatoprost Ophthalmic Solution
42 Comparing Efficacy and Safety of Combigan With Timolol Adjunctive to Xalatan in Glaucoma or Ocular Hypertension Subjects Completed NCT00735449 Phase 4 Fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5%;timolol maleate 0.5%;latanoprost 0.005%
43 A Phase IV Study of Travoprost + Brinzolamide to Treat Glaucoma or Ocular Hypertension Completed NCT00471380 Phase 4 travoprost 0.004% and brinzolamide 1%;fixed combination of timolol 0.5% and dorzolamide 2% plus travoprost vehicle
44 Dry Eye Study With Cosopt® Over 8 Weeks in Patients With Open-Angle Glaucoma or Ocular Hypertension (0507A-152)(COMPLETED) Completed NCT00545064 Phase 4 dorzolamide hydrochloride (+) timolol maleate
45 A Study to Assess the Efficacy of 3 Months of Latanoprost Treatment in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-Angle Glaucoma Completed NCT00647101 Phase 4 Latanoprost
46 24-Hour Intraocular Pressure (IOP) And Blood Pressure Control In Glaucoma And Ocular Hypertension Patients Completed NCT00330577 Phase 4 timolol maleate 0.5%;latanoprost/timolol fixed combination;placebo (artificial tears)
47 Laser-1st vs Drops-1st for Glaucoma and Ocular Hypertension Completed NCT03395535 Phase 4 Primary Medical Treatment Pathway
48 Phase IV Randomised Double-masked Clinical Trial: Assessing Morning Versus Evening Dosing of a Fixed Dose Combination of Travoprost 0.004% / Timolol Maleate 0.5% in Patients With Primary Open-angle Glaucoma or Ocular Hypertension Completed NCT00759239 Phase 4 Travoprost 0.004% / Timolol maleate 0.5%;Travoprost 0.004% / Timolol maleate 0.5%
49 A Single Dose Comfort Comparison of Travatan Z in One Eye Versus Xalatan in the Opposite Eye in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension Completed NCT00527592 Phase 4 Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®);Latanoprost ophthalmic solution 0.005% (XALATAN®)
50 Patient Satisfaction With Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension Completed NCT00804648 Phase 4 Timolol Maleate in Sorbate;Timolol hemihydrate;Timolol maleate gel forming solution

Search NIH Clinical Center for Ocular Hypertension

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: ocular hypertension

Genetic Tests for Ocular Hypertension

Anatomical Context for Ocular Hypertension

MalaCards organs/tissues related to Ocular Hypertension:

38
Eye, Testes, Retina, Endothelial, Brain, Thyroid, Bone

Publications for Ocular Hypertension

Articles related to Ocular Hypertension:

(show top 50) (show all 681)
# Title Authors Year
1
Latanoprostene Bunod 0.024% in Subjects With Open-angle Glaucoma or Ocular Hypertension: Pooled Phase 3 Study Findings. ( 29194198 )
2018
2
The Microbead Occlusion Model of Ocular Hypertension in Mice. ( 29190015 )
2018
3
Expression and activation of mitogen activated protein kinases in the optic nerve head in a rat model of ocular hypertension. ( 29408550 )
2018
4
P2X7 receptor antagonist protects retinal ganglion cells by inhibiting microglial activation in a rat chronic ocular hypertension model. ( 29207073 )
2018
5
The effect of celastrol on the ocular hypertension-induced degeneration of retinal ganglion cells. ( 29398521 )
2018
6
Ocular Hypertension/Glaucoma in Minipigs: Episcleral Veins Cauterization and Microbead Occlusion Methods. ( 29190016 )
2018
7
Calcium channels are involved in EphB/ephrinB reverse signalinga89induced apoptosis in a rat chronic ocular hypertension model. ( 29207174 )
2018
8
Glucocorticoid receptor GRI^ regulates glucocorticoid-induced ocular hypertension in mice. ( 29339763 )
2018
9
Incidence of ocular hypertension after intravitreal injection of anti-VEGF agents in the treatment of neovascular AMD. ( 29450400 )
2017
10
Could White Coat Ocular Hypertension Affect to the Accuracy of the Diagnosis of Glaucoma? Relationships Between Anxiety and Intraocular Pressure in a Simulated Clinical Setting. ( 29119282 )
2017
11
Manipulating ocular endothelial tight junctions: Applications in treatment of retinal disease pathology and ocular hypertension. ( 28951125 )
2017
12
Fixed combination of travoprost and timolol maleate reduces intraocular pressure in Japanese patients with primary open-angle glaucoma or ocular hypertension: analysis by prostaglandin analogue. ( 28053501 )
2017
13
Ciliary body melanoma manifesting as unilateral ocular hypertension and early cataract. ( 29024006 )
2017
14
Efficacy and safety of different regimens for primary open-angle glaucoma or ocular hypertension: a systematic review and network meta-analysis. ( 29144028 )
2017
15
A 3-month safety and efficacy study of travoprost 0.004% ophthalmic solution compared with timolol in pediatric patients with glaucoma or ocular hypertension. ( 28887006 )
2017
16
Prospective Observational Post-Marketing Study of Tafluprost for Glaucoma and Ocular Hypertension: Effectiveness and Treatment Persistence. ( 28502035 )
2017
17
The laser in glaucoma and ocular hypertension (LiGHT) trial. A multicentre randomised controlled trial: baseline patient characteristics. ( 28982956 )
2017
18
Establishment and Characterization of an Acute Model of Ocular Hypertension by Laser-Induced Occlusion of Episcleral Veins. ( 28763561 )
2017
19
1,3-Oxazole-based selective picomolar inhibitors of cytosolic human carbonic anhydrase II alleviate ocular hypertension in rabbits: Potency is supported by X-ray crystallography of two leads. ( 28728897 )
2017
20
Gastrodin protects retinal ganglion cells through inhibiting microglial-mediated neuroinflammation in an acute ocular hypertension model. ( 29062764 )
2017
21
Efficacy and safety of bimatoprost in glaucoma and ocular hypertension in non-responder patients. ( 28861351 )
2017
22
Laser in Glaucoma and Ocular Hypertension (LiGHT) Trial. A multicentre, randomised controlled trial: design and methodology. ( 28903966 )
2017
23
Circumferential Ciliary Body Cysts Presenting as Acute Pigment Dispersion and Ocular Hypertension. ( 28914584 )
2017
24
Preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% in patients with open-angle glaucoma and ocular hypertension: results of an open-label observational study. ( 28652689 )
2017
25
INTRAOCULAR DEXAMETHASONE IMPLANT POSITION IN SITU AND OCULAR HYPERTENSION. ( 29016454 )
2017
26
Relationship between Elevated Intraocular Pressure and Divided Peripapillary Sector Retinal Nerve Fiber Layer Thickness in a Cynomolgus Monkey Laser-Induced Ocular Hypertension Model. ( 28564657 )
2017
27
<i>gem</i> -Dinitroalkyl Benzenes: A Novel Class of IOP-Lowering Agents for the Treatment of Ocular Hypertension. ( 29057050 )
2017
28
Patient considerations in ocular hypertension: role of bimatoprost ophthalmic solution. ( 28744094 )
2017
29
Uveitic Ocular Hypertension and Glaucoma. ( 29265966 )
2017
30
Neuroprotective effect of 5E9-androst-3I^,5,6I^-triol on retinal ganglion cells in a rat chronic ocular hypertension model. ( 28919536 )
2017
31
New furoxan derivatives for the treatment of ocular hypertension. ( 28027869 )
2017
32
Acute ocular hypertension disrupts barrier integrity and pump function in rat corneal endothelial cells. ( 28761172 )
2017
33
Vulnerability study of myelinated and unmyelinated nerve fibers in acute ocular hypertension in rabbit. ( 28901515 )
2017
34
JUN is important for ocular hypertension-induced retinal ganglion cell degeneration. ( 28726785 )
2017
35
Topical Coenzyme Q10 demonstrates mitochondrial-mediated neuroprotection in a rodent model of ocular hypertension. ( 28549843 )
2017
36
Caveolin-1 Protects Retinal Ganglion Cells against Acute Ocular Hypertension Injury via Modulating Microglial Phenotypes and Distribution and Activating AKT pathway. ( 28878269 )
2017
37
Comparison of isolated-check visual evoked potential and standard automated perimetry in early glaucoma and high-risk ocular hypertension. ( 28503434 )
2017
38
Intraocular pressure 1 year after vitrectomy in eyes without a history of glaucoma or ocular hypertension. ( 29200822 )
2017
39
Evaluation of spectral domain optical coherence tomography parameters in ocular hypertension, preperimetric, and early glaucoma. ( 29133640 )
2017
40
Comparison of intraocular pressure-lowering effects of ripasudil hydrochloride hydrate for inflammatory and corticosteroid-induced ocular hypertension. ( 28968412 )
2017
41
Thirteen-Year Follow-up of Optic Disc Hemorrhages in the Ocular Hypertension Treatment Study. ( 27832941 )
2017
42
Corneal hysteresis in patients with glaucoma-like optic discs, ocular hypertension and glaucoma. ( 28068950 )
2017
43
Brimonidine and brinzolamide for treating glaucoma and ocular hypertension; a safety evaluation. ( 28656780 )
2017
44
Risk Factors and the Incidence of Ocular Hypertension After Penetrating Keratoplasty. ( 27027229 )
2016
45
Long-term Safety and Efficacy of Latanoprostene Bunod 0.024% in Japanese Subjects with Open-Angle Glaucoma or Ocular Hypertension: The JUPITER Study. ( 27457469 )
2016
46
Prospective Observational Post-marketing Study of Tafluprost 0.0015%/Timolol 0.5% Combination Ophthalmic Solution for Glaucoma and Ocular Hypertension: Short-Term Efficacy and Safety. ( 27492380 )
2016
47
SAFETY OF INTRAVITREAL DEXAMETHASONE IMPLANT (OZURDEX): The SAFODEX study. Incidence and Risk Factors of Ocular Hypertension. ( 27768641 )
2016
48
A Rare Case of Acute Ocular Hypertensive Episode in a Patient with Chronic Infantile Neurological Cutaneous Articular Syndrome. ( 27247525 )
2016
49
The Relation of White-on-White Standard Automated Perimetry, Short Wavelength Perimetry, and Optic Coherence Tomography Parameters in Ocular Hypertension. ( 27820422 )
2016
50
Factors Influencing the Placebo Effect in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: An Analysis of Two Randomized Clinical Trials. ( 27254076 )
2016

Variations for Ocular Hypertension

Expression for Ocular Hypertension

Search GEO for disease gene expression data for Ocular Hypertension.

Pathways for Ocular Hypertension

GO Terms for Ocular Hypertension

Cellular components related to Ocular Hypertension according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transcription factor AP-1 complex GO:0035976 8.62 FOS JUN

Biological processes related to Ocular Hypertension according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 response to organic cyclic compound GO:0014070 9.5 FOS JUN TXN2
2 response to drug GO:0042493 9.46 FOS HSD11B2 JUN TXN2
3 positive regulation of pri-miRNA transcription by RNA polymerase II GO:1902895 9.43 FOS JUN
4 response to food GO:0032094 9.4 G6PC HSD11B2
5 positive regulation of osteoclast differentiation GO:0045672 9.37 CA2 FOS
6 response to muscle stretch GO:0035994 9.26 FOS JUN
7 glucocorticoid biosynthetic process GO:0006704 8.96 HSD11B1 HSD11B2
8 response to lipopolysaccharide GO:0032496 8.92 EPO FOS JUN PTGFR

Molecular functions related to Ocular Hypertension according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 R-SMAD binding GO:0070412 9.16 FOS JUN
2 transcriptional activator activity, RNA polymerase II transcription factor binding GO:0001190 8.96 FOS JUN
3 11-beta-hydroxysteroid dehydrogenase [NAD(P)] activity GO:0003845 8.62 HSD11B1 HSD11B2

Sources for Ocular Hypertension

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....